middle.news
Clarity Pharmaceuticals Advances Prostate Cancer Radiopharmaceuticals with $178m Cash and US Manufacturing Deal
12:08pm on Friday 31st of July, 2026 AEST
•
Healthcare
Read Story
Clarity Pharmaceuticals Advances Prostate Cancer Radiopharmaceuticals with $178m Cash and US Manufacturing Deal
12:08pm on Friday 31st of July, 2026 AEST
Key Points
Strong $178.3 million cash position supports clinical and commercial activities
Commercial manufacturing agreement signed with Nucleus RadioPharma for US production
Co-PSMA Phase II trial shows 2.6 times more lesion detection than standard care
SECuRE theranostic trial reports multiple participants achieving undetectable disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE